Please login to the form below
cardiovascular diseases
This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
This acquisition is a testament to Prothena’s pioneering work in ATTR amyloidosis and Novo Nordisk’s dedication to advancing new disease-modifying therapies for the benefit of people with cardiovascular ... diseases that are the world’s leading
Latest news
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Mavacamten represents Bristol Myers Squibb’s ongoing dedication to improving
-
EMA updates product information for AZ COVID-19 vaccine
This will include independent experts in haematology, cardiovascular medicine, infectious diseases, virology, neurology, immunology and epidemiology, who will present their views on the reported cases.
-
AstraZeneca forms $2bn gene silencing pact with Silence Tx
Collaboration focuses on cardiovascular, renal, metabolic and respiratory disease. UK biotech Silence Therapeutics has added to its growing stable of pharma partnerships with a wide-ranging collaboration with AstraZeneca in cardiovascular,
-
Bayer signs €250m pact with India’s Curadev for STING drugs
started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.
-
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... He added: “we believe that our deep
More from news
Approximately 5 fully matching, plus 100 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... In Qatar, research into genomics and precision medicine is being used to tackle diseases such as obesity, diabetes and cardiovascular disease.
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
As we continue to follow the science to understand the underlying mechanisms of associated cardiovascular, renal and metabolic diseases, we are working to address shared risk factors and develop solutions designed ... Joris Silon is Senior Vice President,
-
On our best behaviour
The main disease areas of focus have understandably been chronic diseases, including obesity, diabetes, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). ... A shift in behaviour could be very beneficial for pharma. With
-
Can protein degraders unlock ‘undruggable’ drug targets?
Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a ... Big pharma and new start-ups. Arvinas recently attracted a $750m
-
China: AstraZeneca’s new engine for growth and innovation
He says the company is “very confident” of sustaining growth in China, and says its broad portfolio of medicines across oncology, respiratory and cardiovascular, metabolic and renal will help it achieve ... diseases, cardiovascular diseases,
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
McCann Health France strengthens team with two new hires
Initially, she worked on the research and development of new drugs in cardiovascular and metabolic diseases before specialising in oncology and onco-haematology.
-
Genmab hires first chief operating officer
Most recently, he led Bristol-Myers Squibb’s US innovative medicines unit, where he managed a team of over 1000 people focused on immunology and cardiovascular diseases.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;
-
MyoKardia appoints COO and medical affairs VP
Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Further to this, the tests used to diagnose cardiac diseases function differently between men and women. ... However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of
-
World Heart Day 2020: It's time to make our clinical trials more inclusive
September 29th is World Heart Day, a day dedicated to raising awareness about cardiovascular diseases and how everyone can take steps to prevent them. ... Cardiovascular diseases affect ethnic minorities more than white people, with South Asians being
-
Digital therapeutics and their impact on society
This is in part due to the explosive, bordering on unmanageable, increase in chronic diseases, such as cardiovascular disease, diabetes, Alzheimer’s disease, obesity and asthma. ... To solve this problem, our systems must be more efficient and more
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Following a busy year and with a number of new Global and EMEA account wins including two pre-launch products for rare diseases, emotive has strengthened the medical team with the ... in rare diseases such as Gaucher disease and Cushing’s disease
-
World Diabetes Day: Interaction and impact of diabetes on mental health
Diabetes and depression can both increase the risk of both macrovascular complications (such as cardiovascular diseases) [18] and microvascular complications (such as retinopathy, neuropathy and nephropathy) [19].
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
World Heart Day 2020: It's time to make our clinical trials more inclusive
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
Mednet Group
Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
